{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:14Z","timestamp":1759336574238,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.arteri.2020.12.014","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T08:40:45Z","timestamp":1621068045000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S2","title":["Hipertrigliceridemia familiar\/hipertrigliceridemia polig\u00e9nica"],"prefix":"10.1016","volume":"33","author":[{"given":"Carlos","family":"Lahoz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mostaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2020.12.014_bib0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2020.12.014_bib0140","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000 mg\/dL) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0145","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.atherosclerosis.2009.05.024","article-title":"Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study","volume":"207","author":"Valdivielso","year":"2009","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2020.12.014_bib0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.CIR.31.3.321","article-title":"A system for phenotyping hyperlipoproteinemia","volume":"31","author":"Fredrickson","year":"1965","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2020.12.014_bib0155","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1093\/hmg\/ddp361","article-title":"A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia","volume":"18","author":"Hegele","year":"2009","journal-title":"Hum Mol Genet."},{"key":"10.1016\/j.arteri.2020.12.014_bib0160","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/ATVBAHA.111.226365","article-title":"An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia","volume":"31","author":"Johansen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0b013e3283471972","article-title":"Genetic bases of hypertriglyceridemic phenotypes","volume":"22","author":"Johansen","year":"2011","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the Genomic Era: a New Paradigm","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocr Rev."},{"key":"10.1016\/j.arteri.2020.12.014_bib0175","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0180","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J Intern Med."},{"key":"10.1016\/j.arteri.2020.12.014_bib0185","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet."},{"key":"10.1016\/j.arteri.2020.12.014_bib0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/1573399815666190502164131","article-title":"Primary hypertriglyceridemia: a look back on the clinical classification and genetics of the disease","volume":"16","author":"Musambil","year":"2020","journal-title":"Curr Diabetes Rev."},{"key":"10.1016\/j.arteri.2020.12.014_bib0195","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial:A narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2020.12.014_bib0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jacl.2020.01.003","article-title":"The polygenic nature of mild-to-moderate hypertriglyceridemia","volume":"14","author":"Dron","year":"2020","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2020.12.014_bib0215","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2020.12.014_bib0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","article-title":"Postprandial hypertriglyceridemia as a coronary risk factor","volume":"431","author":"Boren","year":"2014","journal-title":"Clin Chim Acta."},{"key":"10.1016\/j.arteri.2020.12.014_bib0225","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2020.12.014_bib0230","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2020.12.014_bib0235","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MOL.0000000000000424","article-title":"Do triglyceride-lowering drugs decrease risk of cardiovascular disease?","volume":"28","author":"Maki","year":"2017","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2020.12.014_bib0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11883-017-0667-9","article-title":"Genetics of triglycerides and the risk of atherosclerosis","volume":"19","author":"Dron","year":"2017","journal-title":"Curr Atheroscler Rep."},{"key":"10.1016\/j.arteri.2020.12.014_bib0245","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.clnu.2017.09.028","article-title":"A systematic review of the epidemiology,pathophysiology and current management of hyperlipidaemic pancreatitis","volume":"37","author":"Adiamah","year":"2018","journal-title":"Clin Nutr."},{"key":"10.1016\/j.arteri.2020.12.014_bib0250","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med."},{"key":"10.1016\/j.arteri.2020.12.014_bib0255","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.pan.2019.06.006","article-title":"Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: Cohort analysis of 1457 patients","volume":"19","author":"Pascual","year":"2019","journal-title":"Pancreatology."},{"key":"10.1016\/j.arteri.2020.12.014_bib0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.medcli.2019.11.003","article-title":"Nuevos tratamientos en la quilomicronemia y en la hiperquilomicronemia","volume":"154","author":"Garc\u00eda-D\u00edaz","year":"2020","journal-title":"Med Clin (Barc)."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:44Z","timestamp":1759325564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"alternative-id":["S0214916821000176"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2020.12.014","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hipertrigliceridemia familiar\/hipertrigliceridemia polig\u00e9nica","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2020.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}